Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86


Genomic analysis drives tailored therapy in poor risk childhood leukemia.

Harrison CJ.

Cancer Cell. 2012 Aug 14;22(2):139-40. doi: 10.1016/j.ccr.2012.07.012.


Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia.

Roberts KG, Morin RD, Zhang J, Hirst M, Zhao Y, Su X, Chen SC, Payne-Turner D, Churchman ML, Harvey RC, Chen X, Kasap C, Yan C, Becksfort J, Finney RP, Teachey DT, Maude SL, Tse K, Moore R, Jones S, Mungall K, Birol I, Edmonson MN, Hu Y, Buetow KE, Chen IM, Carroll WL, Wei L, Ma J, Kleppe M, Levine RL, Garcia-Manero G, Larsen E, Shah NP, Devidas M, Reaman G, Smith M, Paugh SW, Evans WE, Grupp SA, Jeha S, Pui CH, Gerhard DS, Downing JR, Willman CL, Loh M, Hunger SP, Marra MA, Mullighan CG.

Cancer Cell. 2012 Aug 14;22(2):153-66. doi: 10.1016/j.ccr.2012.06.005.


Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group TARGET Project.

Loh ML, Zhang J, Harvey RC, Roberts K, Payne-Turner D, Kang H, Wu G, Chen X, Becksfort J, Edmonson M, Buetow KH, Carroll WL, Chen IM, Wood B, Borowitz MJ, Devidas M, Gerhard DS, Bowman P, Larsen E, Winick N, Raetz E, Smith M, Downing JR, Willman CL, Mullighan CG, Hunger SP.

Blood. 2013 Jan 17;121(3):485-8. doi: 10.1182/blood-2012-04-422691. Epub 2012 Dec 4.


Towards precision medicine in childhood leukemia--insights from mutationally activated cytokine receptor pathways in acute lymphoblastic leukemia.

Izraeli S, Shochat C, Tal N, Geron I.

Cancer Lett. 2014 Sep 28;352(1):15-20. doi: 10.1016/j.canlet.2014.02.009. Epub 2014 Feb 22. Review.


How new advances in genetic analysis are influencing the understanding and treatment of childhood acute leukemia.

Roberts KG, Mullighan CG.

Curr Opin Pediatr. 2011 Feb;23(1):34-40. doi: 10.1097/MOP.0b013e3283426260. Review.


Gene variants offer clues to high-risk childhood ALL.

Jenks S.

J Natl Cancer Inst. 2010 Dec 1;102(23):1752-5. doi: 10.1093/jnci/djq489. Epub 2010 Nov 18. No abstract available.


The molecular genetic makeup of acute lymphoblastic leukemia.

Mullighan CG.

Hematology Am Soc Hematol Educ Program. 2012;2012:389-96. doi: 10.1182/asheducation-2012.1.389. Review.


Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group.

Hertzberg L, Vendramini E, Ganmore I, Cazzaniga G, Schmitz M, Chalker J, Shiloh R, Iacobucci I, Shochat C, Zeligson S, Cario G, Stanulla M, Strehl S, Russell LJ, Harrison CJ, Bornhauser B, Yoda A, Rechavi G, Bercovich D, Borkhardt A, Kempski H, te Kronnie G, Bourquin JP, Domany E, Izraeli S.

Blood. 2010 Feb 4;115(5):1006-17. doi: 10.1182/blood-2009-08-235408. Epub 2009 Nov 24.


IL-7 and TSLP receptors: twisted sisters.

Durum SK.

Blood. 2014 Jul 3;124(1):4-5. doi: 10.1182/blood-2014-05-574327.


Mutation of genes affecting the RAS pathway is common in childhood acute lymphoblastic leukemia.

Case M, Matheson E, Minto L, Hassan R, Harrison CJ, Bown N, Bailey S, Vormoor J, Hall AG, Irving JA.

Cancer Res. 2008 Aug 15;68(16):6803-9. doi: 10.1158/0008-5472.CAN-08-0101.


The V617F mutation in Jak2 is not found in childhood acute lymphoblastic leukaemia.

Sulong S, Case M, Minto L, Wilkins B, Hall A, Irving J.

Br J Haematol. 2005 Sep;130(6):964-5. No abstract available.


Novel activating mutations lacking cysteine in type I cytokine receptors in acute lymphoblastic leukemia.

Shochat C, Tal N, Gryshkova V, Birger Y, Bandapalli OR, Cazzaniga G, Gershman N, Kulozik AE, Biondi A, Mansour MR, Twizere JC, Muckenthaler MU, Ben-Tal N, Constantinescu SN, Bercovich D, Izraeli S.

Blood. 2014 Jul 3;124(1):106-10. doi: 10.1182/blood-2013-10-529685. Epub 2014 May 1.


Understanding the biology of CRLF2-overexpressing acute lymphoblastic leukemia.

Tasian SK, Loh ML.

Crit Rev Oncog. 2011;16(1-2):13-24. Review.


Interleukin 7 and thymic stromal lymphopoietin: from immunity to leukemia.

Tal N, Shochat C, Geron I, Bercovich D, Izraeli S.

Cell Mol Life Sci. 2014 Feb;71(3):365-78. doi: 10.1007/s00018-013-1337-x. Epub 2013 Apr 27. Review.


Tyrosine kinase inhibitor use in pediatric Philadelphia chromosome-positive acute lymphoblastic anemia.

Hunger SP.

Hematology Am Soc Hematol Educ Program. 2011;2011:361-5. doi: 10.1182/asheducation-2011.1.361. Review.


Direct relation between BCR-ABL tyrosine kinase activity and cyclin D2 expression in lymphoblasts.

Deininger MW, Vieira SA, Parada Y, Banerji L, Lam EW, Peters G, Mahon FX, Köhler T, Goldman JM, Melo JV.

Cancer Res. 2001 Nov 1;61(21):8005-13.


Correspondence re: R. Varon et al., Mutations in the Nijmegen breakage syndrome gene (NBS1) in childhood acute lymphoblastic leukemia. Cancer Res., 61: 3570-3572, 2001.

Taylor GM, O'Brien HP, Greaves MF, Ravetto PF, Eden OB.

Cancer Res. 2003 Oct 1;63(19):6563-4; author reply 6565. No abstract available.


Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32).

De Keersmaecker K, Graux C, Odero MD, Mentens N, Somers R, Maertens J, Wlodarska I, Vandenberghe P, Hagemeijer A, Marynen P, Cools J.

Blood. 2005 Jun 15;105(12):4849-52. Epub 2005 Feb 15.


Jak3 expression and genomic sequence in pediatric acute lymphoblastic leukemia.

Wood CM, Goodman PA, Uckun FM.

Leuk Lymphoma. 2002 Dec;43(12):2355-62.


New strategies in acute lymphoblastic leukemia: translating advances in genomics into clinical practice.

Mullighan CG.

Clin Cancer Res. 2011 Feb 1;17(3):396-400. doi: 10.1158/1078-0432.CCR-10-1203. Epub 2010 Dec 13.

Items per page

Supplemental Content

Write to the Help Desk